Cancer drugs

Cancer drugs

Drugs, agents used in the treatment of cancer or conditions related to cancer.

Contributors in Cancer drugs

Cancer drugs

An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor GDC-0973 specifically binds to and ...

Multitargeted tyrosine kinase inhibitor DCC-2036

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor DCC-2036 binds to and inhibits the Bcr-Abl ...

PAK4 inhibitor PF-03758309

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. PAK4 inhibitor PF-03758309 binds to PAK4, inhibiting PAK4 activity and cancer ...

P38/Tie2 kinase inhibitor Arry-614

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule inhibitor of p38 and Tie2 kinases with potential antineoplastic, anti-inflammatory and antiangiogenic activities. P38/Tie2 kinase inhibitor Arry-614 binds to and ...

Hedgehog inhibitor PF-04449913

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signalling pathway with potential antineoplastic activity. Hedgehog inhibitor PF-04449913 appears to inhibit Hh pathway signaling. ...

TPH inhibitor LX1032

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule inhibitor of tryptophan hydroxylase (TPH) with potential antiserotonergic activity. TPH inhibitor LX1032 binds to and blocks the activity of TPH, which may ...

SMO antagonist BMS 833923

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO antagonist BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may ...